Cancer therapy is dictated by risk benefit ratios. For every new therapeutic approved by regulatory agencies, every time a drug is assessed for reimbursement and every time a drug is prescribed in the clinic the Pros (Drug efficacy) are weighed against the Cons (Drug toxicity and cost) as the risk benefit ratio.
The Food and Drug Administration (FDA) and European Medicines Agency (EMA) ideally require a companion diagnostic test for each new cancer drug in the market.
Oxford Cancer Biomarkers (OCB) has developed two biomarker discovery platforms to address both sides of the treatment risk benefit ratio for new therapeutics giving the greatest chance of successful companion diagnostic development.
Toxgnostic studies rebalance the risk benefit ratios for new therapeutics by:
Toxgnostic markers can be used alone or in conjunction with companion diagnostic efficacy markers to enhance the selection of patients that would benefit from drug treatment.
OCB is at the forefront of toxgnostic biomarkers 3 and works with some of the world’s best Genome Wide Association Study (GWAS) experts and oncologists.
Using DNA samples and toxicity profiles from Phase III studies, OCB can supply a toxgnostic signature to be used to increase the likelihood of approval with regulatory agencies.
© Copyright 2017 Oxford Cancer Biomarkers. All Rights Reserved.